A. Leske

发表

The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer

G. Kremmidiotis, D. Inglis, T. Lavranos, 2014, Cancer biology & therapy.

BNC105: A Novel Tubulin Polymerization Inhibitor That Selectively Disrupts Tumor Vasculature and Displays Single-Agent Antitumor Efficacy

M. O'callaghan, B. Flynn, G. Kremmidiotis, 2010, Molecular Cancer Therapeutics.

Abstract 1551: Identification of plasma biomarker concentration changes resulting from the administration of the Vascular Disrupting Agent BNC105 across 3 clinical trials in mesothelioma, ovarian and renal cancer

G. Kremmidiotis, J. Iglesias, A. Leske, 2015 .

A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.

M. Stockler, N. Pavlakis, M. Millward, 2013, Lung cancer.

Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation

J. Desai, M. Rosen, D. Rischin, 2011, Clinical Cancer Research.

A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma

B. Costello, G. Sonpavde, H. Drabkin, 2015, Clinical Cancer Research.

A Phase I / II Trial of BNC 105 P with Everolimus in Metastatic Renal Cell Carcinoma

B. Costello, G. Sonpavde, H. Drabkin, 2015 .

Cancer Therapy : Clinical Clinical , Pharmacodynamic , and Pharmacokinetic Evaluation of BNC 105 P : A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation

J. Desai, M. Rosen, D. Rischin, 2011 .

Molecular Cancer Therapeutics BNC 105 : A Novel Tubulin Polymerization Inhibitor That Selectively Disrupts Tumor Vasculature and Displays Single-Agent Antitumor Efficacy

M. O'callaghan, B. Flynn, G. Kremmidiotis, 2010 .

Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.

David M. Shackleford, D. Chalmers, D. Grobelny, 2011, Journal of medicinal chemistry.

Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)

M. Stockler, P. Beale, D. Sommeijer, 2018, Cancer Chemotherapy and Pharmacology.

A vascular cell-restricted RhoGAP, p73RhoGAP, is a key regulator of angiogenesis.

J. Gamble, G. Goodall, M. Vadas, 2004, Proceedings of the National Academy of Sciences of the United States of America.

A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma

B. Costello, G. Sonpavde, H. Drabkin, 2015, Clinical Cancer Research.

The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer

G. Kremmidiotis, D. Inglis, T. Lavranos, 2014, Cancer biology & therapy.

Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.

David M. Shackleford, D. Chalmers, D. Grobelny, 2011, Journal of medicinal chemistry.

Phase I/II study of a BNC105P/everolimus regimen for progressive metastatic renal cell carcinoma (mRCC) following prior tyrosine kinase inhibitors (Hoosier Oncology Group).

G. Sonpavde, M. Galsky, N. Hahn, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.